Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.
Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as immunotherapeutic treatments of solid tumors. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.
Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2020
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Strike Pharma AB founded?
Strike Pharma AB was founded in 2020.
What industry is Strike Pharma AB in?
Strike Pharma AB operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Strike Pharma AB based?
Strike Pharma AB is headquartered in Uppsala, Sweden.
Find investors for your startup like Strike Pharma AB
Gritt sends AI-personalised outreach to each investor — from your Gmail
